1-9 of 9
Isaac W. Boss
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan G. Thompson, Daniel Lopes De Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2024) 144 (Supplement 1): 4585.
https://doi.org/10.1182/blood-2024-194929
Published: 2024
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, Maria Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig C. Hofmeister, Paula Rodriguez Otero, Maria Aranzazu Bermúdez, Thomas Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier De La Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Costa
Journal: Blood
Blood (2023) 142 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2023-180013
Published: 2023
Journal Articles

Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 6247–6249.
https://doi.org/10.1182/blood-2022-156460
Published: 2022
Journal Articles

Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models

Bruno Paiva, Bonny Gaffney, Kelven Burnett, Paola Castiglioni, Michael Angelo, Daniel W. Pierce, Isaac W. Boss
Journal: Blood
Blood (2022) 140 (Supplement 1): 7054–7055.
https://doi.org/10.1182/blood-2022-157987
Published: 2022
Journal Articles

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Isaac W. Boss, Ethan Thompson, Allison M. Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 7116–7117.
https://doi.org/10.1182/blood-2022-163192
Published: 2022
Journal Articles

Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing

Bonny Gaffney, Yu Shi, Petrus de Jong, Manuel Sanchez, Celia Fontanillo, Antonia Lopez-Girona, Isaac W. Boss, Antonina Kurtova, Soraya Carrancio, Lilly Wong, Daniel W. Pierce
Journal: Blood
Blood (2022) 140 (Supplement 1): 7108–7109.
https://doi.org/10.1182/blood-2022-157939
Published: 2022
Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta
Journal: Blood
Blood (2022) 140 (Supplement 1): 7070–7071.
https://doi.org/10.1182/blood-2022-157927
Published: 2022
Journal Articles

Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 8910–8911.
https://doi.org/10.1182/blood-2022-158592
Published: 2022
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 400–402.
https://doi.org/10.1182/blood-2022-159009
Published: 2022